P
Paula Clancy
Researcher at James Cook University
Publications - 47
Citations - 1951
Paula Clancy is an academic researcher from James Cook University. The author has contributed to research in topics: Aortic aneurysm & Atheroma. The author has an hindex of 25, co-authored 47 publications receiving 1791 citations. Previous affiliations of Paula Clancy include Townsville Hospital.
Papers
More filters
Journal ArticleDOI
Association of statin prescription with small abdominal aortic aneurysm progression.
Craig D. Ferguson,Paula Clancy,Bernhard Bourke,Phillip J. Walker,Anthony E. Dear,Tim Buckenham,Paul Norman,Jonathan Golledge +7 more
TL;DR: The results do not support the findings of smaller studies and suggest that statin treatment and serum low-density lipoprotein concentrations may have no benefit in reducing AAA progression.
Journal ArticleDOI
Reduced expansion rate of abdominal aortic aneurysms in patients with diabetes may be related to aberrant monocyte–matrix interactions
Jonathan Golledge,Mirko Karan,Corey S. Moran,Juanita Muller,Paula Clancy,Anthony E. Dear,Paul Norman +6 more
TL;DR: It is confirmed that the progression of AAA is slower in patients with diabetes and a mechanism by which the aortic media may be protected from degradation in these individuals is suggested.
Journal ArticleDOI
Obesity, adipokines, and abdominal aortic aneurysm: health in men study
TL;DR: Serum resistin concentrations were more strongly associated with aortic diameter than adipokines that are more intimately associated with adiposity, and measures of obesity are independently associated with AAA.
Journal ArticleDOI
Association Between Osteopontin and Human Abdominal Aortic Aneurysm
Jonathan Golledge,Juanita Muller,Neil Shephard,Paula Clancy,Linda Smallwood,Corey S. Moran,Anthony E. Dear,Lyle J. Palmer,Paul Norman +8 more
TL;DR: Serum and tissue concentrations of OPN are associated with human aortic aneurysm and OPN may be a useful biomarker for AAA presence and growth.
Journal ArticleDOI
On a mouse monoclonal antibody that neutralizes all four dengue virus serotypes
Ravikumar Rajamanonmani,Céline Nguefeu Nkenfou,Paula Clancy,Yin Hoe Yau,Susana Geifman Shochat,Soila Sukupolvi-Petty,Wouter Schul,Michael S. Diamond,Subhash G. Vasudevan,Subhash G. Vasudevan,Julien Lescar +10 more
TL;DR: Its virus inhibition activity and broad cross-reactivity makes mAb 9F12 a suitable candidate for optimization and humanization into a therapeutic antibody to treat severe infections by dengue.